Inside Precision Medicine September 19, 2024
A recent study from researchers in South Korea contends that certain diabetes medications known as sodium-glucose cotransporter-2 (SGLT2) inhibitors may be linked to a reduced risk of developing dementia and Parkinson’s disease. The findings, published this week in the journal Neurology, are significant given the rising prevalence of these neurodegenerative diseases, especially among individuals with type 2 diabetes.
SGLT2 inhibitors, commonly referred to as gliflozins, work by helping the kidneys excrete excess glucose through urine, which, in turn, lowers blood sugar levels. This class of drug has gained popularity both for its glucose-lowering effects to treat type 2 diabetes and its potential cardiovascular benefits.
“We know that these neurodegenerative diseases are common and the number of cases is growing as...
Today's Sponsors
Today's Sponsor